Cancer Immunotherapy: Global Market to Reach $160.24 Billion by 2023 - Report Analysis on Product Type, Cancer Type, End-User and Geography - ResearchAndMarkets.com
Jun. 14, 2018
DUBLIN--(BUSINESS WIRE)--Jun 14, 2018--The "Cancer Immunotherapy - Global Market Outlook (2017-2023)" report has been added to ResearchAndMarkets.com's offering.
The Global Cancer Immunotherapy market accounted for $62.57 billion in 2016 and is expected to reach $160.24 billion by 2023 growing at a CAGR of 14.3% from 2016 to 2023.
Rapid increase in cases of cancer across the globe, technical advancement in treatment therapies, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment and lack of awareness are the restraints hampering the market. On the other hand rise in clinical trials against different cancers in immunotherapy and elevated expansion prediction in developing countries are some opportunities for the market over the forecast period.
Based on product, the monoclonal antibodies are made by single clone of cells or cell line and are comprised of identical antibody molecules. The factors such as growing occurrence of cancer and other chronic diseases, rising awareness among patients and rising requirement for personalized medicine are favoring this product's segment.
In terms of geography, North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.
Product TypesImmune Checkpoint Inhibitors Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) Cancer Monoclonal Antibodies Conjugated Monoclonal Antibodies Bispecific Monoclonal Antibodies Naked Monoclonal Antibodies Immunomodulators Oncolytic Virus Interleukins (IL) Interferons (IFN) Cancer Vaccines Prophylactic Vaccines Therapeutic Vaccines Cell Therapies Chimeric Antigen Receptor (CAR) T Cell Therapy Dendritic Cells
Cancer TypesBreast Cancer Colorectal Cancer Head & Neck Cancer Multiple Myeloma Melanoma Lung Cancer Prostate Cancer Ovarian Cancer Pancreatic Cancer Other Cancer Types
End UsersHospital Clinics Other End Users
Key Topics Covered
1 Executive Summary
3 Market Trend Analysis
4 Porters Five Force Analysis
5 Global Cancer Immunotherapy Market, By Product Type
6 Global Cancer Immunotherapy Market, By Cancer Type
7 Global Cancer Immunotherapy Market, By End-User
8 Global Cancer Immunotherapy Market, By Geography
9 Key Developments
10 Company ProfilingBristol-Myers Squibb F. Hoffmann-LA Roche Ltd GlaxoSmithKline Pfizer Eli Lilly and Company Janssen Global Services, LLC (Johnson and Johnson) Novartis Amgen Inc. Biovest International Inc Ablynx NV Genentech Inc Bellicum Pharmaceuticals Inc Bayer AG Oxford BioTherapeutics Ltd. Merck Sydys Corporation Dendreon Xencor Daiichi Sankyo TG Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/v2jlkz/cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006149/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/14/2018 03:39 PM/DISC: 06/14/2018 03:39 PM